Oncology Drug Market Strategy
The client, a biotechnology company, wanted a go-to-market diagnostic test strategy for novel oncology drug with a focus on next-generation sequencing NGS vs. IHC.
- United Kingdom
- United States
8 + 250
Qualitative + Quantitative
– Medical Lab Scientist
– Consultant Pathologist
– Laboratory Manager
– Laboratory Director
Patient flow and diagnostic test processes were mapped across multiple clinic business models.
- The drivers and hurdles to NGS adoption were identified.
- NGS, liquid biopsy, and IHC are all expected to be used in the future.
- Alternatives and recommendations for a companion diagnostic strategy.